Publications and presentations

AVEO Oncology allows you to access a number of published papers and presentations outlining our clinical data that were given at premier conferences and symposia around the world.

June 10, 2022
PresentationTivozanib

ASCO 2022: Activity of Tivozanib in Non-Clear Cell Renal Cell Carcinoma (nccRCC): Subgroup Analysis From a Phase 2 Randomized Discontinuation Trial

June 10, 2022
PresentationTivozanib

ASCO 2022: Maturation of Overall Survival in TIVO-3 With Long-Term Follow-Up

February 14, 2022
PresentationTivozanib

ASCO GU 2022: TiNivo-2: A Phase 3, Randomized, Controlled, Open-Label Study to Compare Tivozanib in Combo With Nivolumab to Tivozanib Monotherapy in Patients With RCC Following 1 or 2 Lines of Therapy in Which at Least One Line Has an Immune CPI

February 14, 2022
PresentationTivozanib

ASCO GU 2022: Long-Term PFS From TIVO-3: Tivozanib (TIVO) vs Sorafenib (SOR) in Relapsed/Refractory (R/R) Advanced RCC

January 24, 2022
PresentationTivozanib

ASCO GI 2022: A Phase 1b/2 Open Label Study of Tivozanib in Combination with Durvalumab in Subjects with Advanced Hepatocellular Carcinoma: DEDUCTIVE

January 24, 2022
PresentationTivozanib

ASCO GI 2022: A Phase 1b/2 Study of Tivozanib in Combination with Durvalumab in Subjects with Advanced Hepatocellular Carcinoma (DEDUCTIVE): Efficacy Results in Previously Untreated Patients

1 2 3 4 5 … 14

Looking for medical information? Contact our Medical Information Team at

AVEOmedicalinformation@aveooncology.com.